Aryl substituted diazabicyclooctanes (DBO) compounds that inhibit β-lactamases of class A, class C or class D and potentiate β-lactam antibiotics are disclosed. In particular, this disclosure provides DBO compounds that, when used in the disclosed Synergy MIC Assay with a β-lactam antibiotic at a fixed concentration have an MIC of 8 μg/mL or less against one or more isogenic β-lactamase expressing bacterial strains.
本文披露了取代芳基的二
氮杂双
环辛烷(DBO)化合物,可抑制A类、C类或D类β-内
酰胺酶,并增强β-内
酰胺类
抗生素的作用。特别是,本文提供了DBO化合物,当与β-内
酰胺类
抗生素在固定浓度下在披露的协同MIC测定中使用时,对一个或多个表达β-内
酰胺酶的同源细菌菌株的MIC为8μg/mL或更低。